You have accessJournal of UrologyProstate Cancer: Markers (MP60)1 Sep 2021MP60-14 POST-BIOPSY CELL-FREE DNA IN BLOOD AS A TOOL FOR MOLECULAR TESTS IN LOCALIZED PROSTATE CANCER Marinella Corbetta, Chiara Chiereghin, Ilaria De Simone, Giulia Soldà, Monica Zuradelli, Michele Giunta, Davide Maffei, Giovanni Lughezzani, Nicolò Maria Buffi, Rodolfo Hurle, Alberto Rosario Saita, Paolo Casale, Rosanna Asselta, Massimo Lazzeri, Giorgio Ferruccio Guazzoni, and Stefano Duga Marinella CorbettaMarinella Corbetta More articles by this author , Chiara ChiereghinChiara Chiereghin More articles by this author , Ilaria De SimoneIlaria De Simone More articles by this author , Giulia SoldàGiulia Soldà More articles by this author , Monica ZuradelliMonica Zuradelli More articles by this author , Michele GiuntaMichele Giunta More articles by this author , Davide MaffeiDavide Maffei More articles by this author , Giovanni LughezzaniGiovanni Lughezzani More articles by this author , Nicolò Maria BuffiNicolò Maria Buffi More articles by this author , Rodolfo HurleRodolfo Hurle More articles by this author , Alberto Rosario SaitaAlberto Rosario Saita More articles by this author , Paolo CasalePaolo Casale More articles by this author , Rosanna AsseltaRosanna Asselta More articles by this author , Massimo LazzeriMassimo Lazzeri More articles by this author , Giorgio Ferruccio GuazzoniGiorgio Ferruccio Guazzoni More articles by this author , and Stefano DugaStefano Duga More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002095.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The analysis of circulating cell-free DNA (ccfDNA) and its tumoral fraction, the circulating tumor DNA (ctDNA), represents an innovative strategy for cancer management. It can provide information on the molecular profile of patients, useful for early cancer diagnosis and monitoring. However, considering localized prostate cancer (PCa), the presence of a pseudo-capsule surrounding the organ limits the release of ccfDNA in the circulation and its tumoral fraction is under the threshold for detection. We hypothesized that during the biopsy the needle punctures performed on the organ are likely to cause a release of prostate-derived ccfDNA, suitable for further molecular tests. METHODS: We collected needle biopsies and a blood sample (3 mL) before the start of the biopsy procedure from 38 patients undergoing transperineal prostate biopsy. A second blood sample was collected at the end of the procedure, at different sampling times: for 13 patients after 60 minutes, for 19 after 120 minutes and for 6 patients 4 post-biopsy blood samples were taken (after 10, 30, 60 and 120 minutes). ccfDNA was extracted from 1 mL of plasma using the Maxwell RSC ccfDNA Plasma Kit (Promega) and quantified with a Qubit fluorometer (Thermo Fisher). The size distribution analysis was performed using a TapeStation (Agilent). Patients’ specific somatic mutations were identified with the TruSight RNA PanCancer panel (Illumina) on bioptic material and were searched in ccfDNA of the corresponding patient using a targeted sequencing (NEBNext Ultra II DNA Library Prep kit, NEB) of selected amplicons. RESULTS: We demonstrated a significant increase in the amount of ccfDNA after the biopsy procedure, both after 60 and 120 minutes (P≤0.0024). The size distribution analysis revealed the presence of longer DNA molecules, up to 1 kb, in the post-biopsy samples compared to the pre-biopsy condition. Longer molecules are probably prostate-derived and freshly released after the end of the biopsy, not yet being degraded by nucleases in the circulation. Five patient-specific somatic variants were detected with an experiment of targeted RNA-sequencing performed on needle biopsy samples. The NGS analysis of amplicons targeting the selected variants in pre- and post-biopsy ccfDNA in the corresponding patients revealed an enrichment in ctDNA (from 2.2 to 164 fold) in the post-biopsy sample CONCLUSIONS: This study opens the possibility of exploiting the enrichment of ctDNA in the post-biopsy condition for the analysis of somatic mutations/epigenetic modifications in ccfDNA for the first time in the context of localized PCa. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1047-e1047 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Marinella Corbetta More articles by this author Chiara Chiereghin More articles by this author Ilaria De Simone More articles by this author Giulia Soldà More articles by this author Monica Zuradelli More articles by this author Michele Giunta More articles by this author Davide Maffei More articles by this author Giovanni Lughezzani More articles by this author Nicolò Maria Buffi More articles by this author Rodolfo Hurle More articles by this author Alberto Rosario Saita More articles by this author Paolo Casale More articles by this author Rosanna Asselta More articles by this author Massimo Lazzeri More articles by this author Giorgio Ferruccio Guazzoni More articles by this author Stefano Duga More articles by this author Expand All Advertisement Loading ...